Sangamo Therapeutics (SGMO) shares slumped over -30% lower due to a failed Phase 1/2 study. The company reported its SB-318 genome editing product did not appear to show any clinical benefits. The company does have an extensive pipeline of treatments in clinical trials, as well as partnerships with major companies such as Pfizer. However, this was not enough for traders to keep the price stable near yesterday’s close. Here’s a recap.
Written By: Howard Greenberg As everyday traders put their trading plans into action for 2026, penny stocks might not be on many of their radars. It’s totally understandable why penny stocks may not appeal to the more calculated seasoned traders. Their reputations for susceptibility to manipulation, extreme volatility, and low liquidity make them way too […]
Read Article
A high-profile policy debate has re-entered the financial spotlight surrounding credit card interest rate caps. Last week, President Donald Trump called for a temporary national cap on credit card interest rates. He proposed a maximum annual rate of 10% over a one-year period, starting January 20, 2026. President Trump’s proposal would aim to combat the […]
Read Article
Make no mistake…day trading options can be very profitable, but it can also be very risky. If you don’t know what you’re doing—you will get burned. When I first started day trading options, I learned that lesson the hard way quite a few times, but those experiences made me a better trader and coach. I’ll […]
Read Article
A lot of traders probably never heard of AGRZ stock. In a nutshell, it’s an agricultural technology company that specializes in building, managing, and operating indoor Controlled Environment Agriculture vertical farms. The stock began trading on the Nasdaq in October 2025. It’s largely been considered a penny stock, which hit highs above $5 since its […]
Read Article
It’s a known fact that precious metals like gold and silver can profoundly affect the US dollar’s performance and value. Just this year, we saw gold and silver prices jump in late-January, while the US Dollar Index fell considerably around that same time. In the weeks since, the US Dollar, along with gold, silver, and […]
Read Article
When asked about kicking off market action for this week, Scott Bauer gave a very blunt answer: “Volatility, and we don’t know what’s next.” That first question kicked off Scott’s most recent appearance on the Schwab Network’s “Big 3” segment earlier this week. Scott touched on the unpredictable landscape traders are currently facing, and highlighted […]
Read ArticleWe choose to let our members and students speak for themselves. We do not actively solicit testimonials, no compensation has been paid for any testimonial, and testimonials are not necessarily representative of the experience of all students. All monetary claims made in testimonials that you see depicted in our marketing material have been verified by Prosper Trading Academy and attested to by the members that have given them. Verified testimonials encompass “experience” reviews that highlight the personal experiences of working with our team and “performance” testimonials where we verify trading success of students who have enrolled in our programs.Given the broad reach of the internet, testimonials and reviews of our programs that we have not been able to verify can be found on various websites across the internet which are beyond our editorial control. While we do very much enjoy hearing positive things from our students and it is critical to our mission that everyone is satisfied with their journey with Prosper, we encourage you to take both verified and unverified testimonials for what they are.